Mixed Salts of a Single-Entity Amphetamine - A Detailed Review

Overview:

One medicine used to manage and treat narcolepsy- drowsy the whole day and ADHD (neurodevelopmental disorder that affects attention and behavior and hyperactivity) is Amphetamine. It is categorized as a stimulant of the central nervous system. This exercise goes over the uses, side effects, and precautions of Amphetamine as a medication for narcolepsy and ADHD. The mechanism of action, side effect profile, and other important details (such as dosage, monitoring, and toxicity) that are important for the interprofessional team members to know about while treating patients with ADHD and narcolepsy will be highlighted in this exercise.

The FDA- Food and Drug Administration has approved Amphetamine for the treatment of narcolepsy and attention-deficit or hyperactivity disorder (ADHD). Its indications include treating adults and children six years of age and older with it as a first-line treatment for ADHD. Another second-line medication for narcolepsy treatment is Amphetamine. The FDA has approved the long-acting Amphetamine drug Lisdexamfetamine for the management of binge-eating disorders.

For Patients:

What Is the Use of Amphetamine Product Called Mixed Salts of a Single Entity?

A prescription medication called mixed salts of a single entity Amphetamine is used to treat the following conditions involving the central nervous system (CNS) stimulant:

• Children aged three to 17 with attention-deficit hyperactivity disorder (ADHD). For those with ADHD, mixed salts of a single-entity Amphetamine product may assist in improving focus while reducing impulsivity and hyperactivity.

• A sleep ailment in adults six years of age and older is known as narcolepsy. The safety and efficacy of mixed salts of a single-entity Amphetamine product in children with ADHD under the age of three is unknown. The safety and effectiveness of mixed salts of a single-entity Amphetamine product in children with narcolepsy under the age of six is unknown.

Because it contains Amphetamine, which can be abused by those who abuse prescription medications or illicit drugs, mixed salts of a single entity Amphetamine product are classified as federally controlled substances (CII). To prevent theft, store mixed salts of a single entity Amphetamine product in a secure location. Never offer someone else your mixed salts of a single entity Amphetamine product, as it could kill or seriously hurt them. It is illegal to sell or give away mixed salts of a single Amphetamine product because they may cause harm to other people.

How Should One Take Mixed Salts of A Single Amphetamine Product?

Adhere to your doctor's prescription for mixed salts of a single entity Amphetamine medication precisely as directed. If necessary, your healthcare provider may adjust the dosage.

• You typically take your first dose of the day as soon as you wake up.

• You can take mixed salts of a single Amphetamine product with or without food.

What Adverse Consequences Could Mixed Salts of a Single Amphetamine Product Cause?

A single-entity Amphetamine product's mixed salts can have major adverse effects, such as:

• A decrease in children's height and weight growth. Throughout treatment with mixed salts of a single entity Amphetamine product, children should have frequent weight and height assessments. If your child is not growing or gaining weight as planned, your healthcare professional may decide to stop treating them with mixed salts of a single-entity Amphetamine medication.

• Convulsions. Suppose you or your child experiences a seizure (abnormal electrical spikes in the brain). In that case, your healthcare professional may decide to discontinue treatment with mixed salts of a single entity Amphetamine medication.

• Issues with circulation in the fingers and toes (which include Raynaud's phenomenon (restricted blood flow to the extremities) and peripheral vasculopathy- slow blood vessel disorder). Among the symptoms and indicators are:

• Neuralgia or pain in the fingers or toes may be felt.

• The color of fingers or toes may shift from pale to blue to red.

• Inform your healthcare practitioner if you or your kid has any of the following in your fingers or toes: numbness, discomfort, change in skin color, or temperature sensitivity.

Adverse effects that must need special attention:

• Serotonin Syndrome: This potentially fatal issue can arise when certain additional medications are used with mixed salts of a single entity Amphetamine product. If you or your child exhibit any of the following serotonin syndrome signs and symptoms, stop consuming mixed salts of a single entity Amphetamine product and contact your healthcare provider or head to the nearest hospital emergency department right away:

• Agitation, delusions, unconsciousness.

• Rapid heart rate.

• Flushing.

• Lack of coordination.

• Seizures.

• Perplexity- Inability to understand something.

• Disorientation.

• Changes in blood pressure, fever, sweating, nausea, vomiting, diarrhea (loose, watery stool in a day 3-4 times), Tightness or stiffness in the muscles, and elevated body temperature (hyperthermia).

• The onset of new or worsening Tourette's syndrome (sudden involuntary movements called tics) symptoms.

Common Side Effects:

The following are the most typical adverse effects of mixed salts of a single-entity Amphetamine product:

• Indigestion.

• Decreased appetite.

• Anxiety.

For Doctors:

Clinical Pharmacology:

Pharmacodynamics: Amphetamines are sympathomimetic amines that do not include catecholamines and possess CNS-stimulating properties. It is unknown how therapy for attention deficit hyperactivity disorder (ADHD) works. It is believed that Amphetamines increase the release of norepinephrine and Dopamine into the extraneuronal region by preventing their absorption into the presynaptic neuron.

Pharmacokinetics:

The ratio of d-amphetamine to l-amphetamine salts is 3:1 in mixed salts of a single-entity Amphetamine product. Peak plasma concentrations for both d-and l-amphetamine occurred about three hours after a single dose of 10 mg (milligrams) or 30 mg of mixed salts of a single entity Amphetamine product was given to healthy volunteers while they were fasting.

Compared to the l-isomer, the mean elimination half-life (t½) of d-amphetamine was shorter. When d- and l-amphetamine were taken from 10 mg to 30 mg, their PK parameters (Cmax, AUC0-inf) increased by around three times, demonstrating dose-proportional pharmacokinetics. It has not been investigated how meals affect the bioavailability of mixed salts of a single-entity Amphetamine product.

Excretion and Metabolism:

According to reports, Amphetamine can be oxidized at position four of the benzene ring to generate 4-hydroxyamphetamine or on the side chain's α or β carbons to form norephedrine or alpha-hydroxyamphetamine, respectively. Both 4-hydroxy-amphetamine and norephedrine are active substances that are later oxidized to produce 4-hydroxy-norephedrine.

After deamination, alpha-hydroxy-amphetamine yields phenylacetone, which in turn yields benzoic acid, its glucuronide, and the glycine conjugate hippuric acid. CYP2D6 is recognized to be involved in Amphetamine metabolism, even though the precise enzymes involved are still unknown.

While the precise enzymes responsible for the metabolism of Amphetamines remain unclear, CYP2D6 is recognized for its role in the production of 4-hydroxyamphetamine. A possible explanation for population variability in Amphetamine metabolism is the genetic polymorphism of CYP2D6.

Indications:

The therapy of Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy is advised for Dextroamphetamine saccharate, Amphetamine aspartate, Dextroamphetamine sulfate, and Amphetamine sulfate tablets (mixed salts of a single entity Amphetamine product).

ADHD stands for attention deficit hyperactivity disorder. When hyperactive-impulsive or inattentive symptoms that produced impairment and appeared before the age of seven years old are present, it is assumed that the patient has attention deficit hyperactivity disorder (ADHD; DSM-IV).

The symptoms must be present in two or more contexts, such as home, work, or school, and they must cause a clinically substantial impairment in social, intellectual, or occupational performance. No other mental illness more adequately explains the symptoms. At least six symptoms need to have lasted for at least six months to qualify as the Inattentive Type.

Contraindications:

In those who are recognized to be hypersensitive to Amphetamine or other substances found in combination salts of an Amphetamine product. Patients receiving treatment with different Amphetamine medications have reported experiencing hypersensitivity events, including angioedema and anaphylactic reactions.

Individuals having a higher risk of hypertensive crises who are taking monoamine oxidase inhibitors (MAOIs) or who will stop taking them within 14 days (including those receiving linezolid or intravenous methylene blue).

Warnings and Precautions:

Misuse, Addiction, and Abuse:

There is a significant risk of abuse and misuse with Dextroamphetamine saccharate, Amphetamine aspartate, Dextroamphetamine sulfate, and Amphetamine sulfate. People who use Amphetamine aspartate, Dextroamphetamine saccharate, Amphetamine sulfate, or both run the risk of abusing or misusing these drugs, which can result in the emergence of addiction or other substance use disorders.

Amphetamine aspartate, Dextroamphetamine sulfate, Amphetamine sulfate, and Dextroamphetamine saccharate can be diverted into illegal channels or distribution for non-medical use. A higher risk of overdose and death can arise from the misuse and abuse of CNS stimulants, such as Dextroamphetamine saccharate, Amphetamine aspartate, Dextroamphetamine sulfate, and Amphetamine sulfate. Higher doses and unapproved methods of administration, like snorting or injection, can exacerbate this risk.

Hazards for Individuals With Severe Heart Disease:

Patients receiving CNS stimulant therapy at the authorized dosages for ADHD who also had structural cardiac abnormalities or other significant cardiac diseases have been known to die suddenly.

Avoid giving patients who have known structural cardiac abnormalities, cardiomyopathy, significant cardiac arrhythmia, coronary artery disease, or other serious cardiac diseases Dextroamphetamine saccharate, Amphetamine aspartate, or Dextroamphetamine sulfate.

Elevated Heart Rate and Blood Pressure:

Blood pressure and heart rate are raised by CNS stimulants, with a mean increase of two to four mm Hg (millimeters of mercury) and three to six bpm (beats per minute), respectively. More significant rises may occur in some cases. Keep an eye out for any potential tachycardia and hypertension in patients receiving Dextroamphetamine saccharate, Amphetamine aspartate, Dextroamphetamine sulfate, or Amphetamine sulfate treatment.

Psychiatric Adverse Events:

Deficiency of Preexisting Psychosis Severe:

For people who already suffer from a psychotic disease, CNS stimulants may make their symptoms of thinking disorder and behavior disturbance worse.

Inducing Manic Episodes in Bipolar Disorder Patients:

Patients taking CNS stimulants may experience a mixed or manic episode. Screen patients for manic episode risk factors (such as co-occurring depression, a history of depressive symptoms, or a family history of depression, bipolar disorder, or suicide) before starting medication.

Fresh Manic or Psychotic Symptoms:

When used at appropriate dosages, CNS stimulants may induce psychotic or manic symptoms in patients who have never had psychotic disease or mania before, such as delusional thinking, hallucinations, or mania. Psychotic or manic symptoms were observed in several short-term, placebo-controlled investigations using CNS stimulants that were combined and analyzed.

Drug Interactions:

MAO Inhibitors:

A hypertensive crisis can result from taking MAOIs and CNS stimulants at the same time. Death, stroke, myocardial infarction, aortic dissection, issues related to the eyes, eclampsia, pulmonary edema, and renal failure are possible results. If you stop using MAOI for more than 14 days, you should not take Dextroamphetamine saccharate, Amphetamine aspartate, Dextroamphetamine sulfate, or Amphetamine sulfate concurrently.

Serotonergic Substances:

Serotonin syndrome is more likely to occur when Dextroamphetamine saccharate, Amphetamine aspartate, Dextroamphetamine sulfate, Amphetamine sulfate, and Serotonergic medications are used concurrently. Start at lower dosages and keep an eye out for serotonin syndrome symptoms in patients, especially when starting or increasing dosages of Amphetamine sulfate, Dextroamphetamine saccharate, Amphetamine aspartate, or Dextroamphetamine sulfate. Stop taking Amphetamine aspartate, Dextroamphetamine saccharate, Amphetamine sulfate, and any concurrent serotonergic medication(s) if serotonin syndrome develops.

Inhibitors of CYP2D6:

When Dextroamphetamine saccharate, Amphetamine aspartate, Dextroamphetamine sulfate, Amphetamine sulfate, and CYP2D6 inhibitors are used together, they may be exposed to higher levels of these substances than if they were taken alone. They may also raise the risk of serotonin syndrome. Start with smaller dosages and keep an eye out for serotonin syndrome symptoms in patients, especially when starting Dextroamphetamine saccharate, Amphetamine aspartate, and Amphetamine sulfate, and after increasing the dosage.

Acid-producing Substances:

Reduced Amphetamine blood levels and effectiveness. Depending on the clinical response, raise the dose. Urinary and gastric acidifying agents are a couple of examples of acidifying agents.

Adrenergic Inhibitors:

Amphetamines inhibit adrenergic blockers.

Alkalinising Substances:

Elevate blood levels and intensify Amphetamine's effects. It is best to avoid co-administration of gastrointestinal alkalinizing medications with Dextroamphetamine saccharate, Amphetamine aspartate, Dextroamphetamine sulfate, and Amphetamine sulfate. Urinary and gastrointestinal alkalinizing agents are a couple of examples of alkalinizing agents.

Tricyclic Depression Medicines:

Increased activity of tricyclic or sympathomimetic drugs may intensify the effects on the cardiovascular system, resulting in notable and long-lasting increases in the brain's d-amphetamine concentration. Continually monitor, modify, or switch to an alternate therapy depending on the clinical response.

Histamine Inhibitors:

Amphetamines may offset antihistamines' sedative effect.

Medication in Special Scenario:

1. The Teratogenic Effects of Pregnancy:

Oral administration of Amphetamine at doses up to six mg/kg/day (milligram per kilogram per day) and 16 mg/kg/day to pregnant rats and rabbits during the organogenesis period did not appear to have any effect on embryofetal morphological development or survival in the enantiomer ratio present in mixed salts of a single entity Amphetamine product (d- to l- the ratio of 3:1).

Based on an mg/m2 body surface area basis. These doses are roughly 1.5 and eight times the maximum recommended human intake of 30 mg/day (child). Parenterally administered d-amphetamine doses of 50 mg/kg/day (about six times that of a human dose of 30 mg/day (kid) on an mg/m2 basis) or higher to pregnant animals have been linked to fetal abnormalities and mortality in mice.

2. Effects That Are Not Teratogenic:

Mothers who are Amphetamine dependent are more likely to give birth to premature babies and babies with low birth weights. Additionally, these babies may have dysphoria, which manifests as agitation and marked lassitude, as withdrawal symptoms.

3. Use in Mothers Who Are Nursing:

Human milk contains expelled Amphetamines. It should be noted that mothers taking Amphetamines should not breastfeed.

4. Use in Paediatrics:

Amphetamine use in youngsters has not been shown to have long-term impacts. It is not advised to use Amphetamines in children with Attention Deficit Hyperactivity Disorder under the age of three.

5. Geriatric Usage:

The elderly population has not been the subject of any research on mixed salts of a single-entity Amphetamine product.

Adverse Effects:

• Cardiovascular Responses: Heart palpitations, tachycardia, hypertension, myocardial infarction, and abrupt death. A few cases of cardiomyopathy linked to long-term Amphetamine usage have been reported.

• Central Nervous System: Overstimulation, restlessness, irritability, euphoria, dyskinesia, dysphoria, depression, tremors, motor and verbal tics, aggression, hostility, logorrhoea, and dermatillomania are all associated with appropriate dosages of psychotic episodes.

• Vision Issues: Mydriasis and fuzzy vision.

• Gastrointestinal: Gastrointestinal disorders such as intestinal ischemia, diarrhea, constipation, dry mouth, and sour taste. Weight loss and anorexia are possible side effects.

• Intolerance: Hypersensitivity responses, such as urticaria, rash, angioedema, and anaphylaxis. There have been reports of severe skin rashes, including toxic epidermal necrolysis and Stevens-Johnson syndrome.

• Hormonal: Impotence, libido fluctuations, and prolonged or frequent erections.

• Aesthetics Related: Hair loss.

• Skeletal Muscle: Rhabdomyolysis.